Faber J, Lumholtz I B, Kirkegaard C, Poulsen S, Jørgensen P H, Siersbaek-Nielsen K, Friis T
J Clin Endocrinol Metab. 1985 Dec;61(6):1093-9. doi: 10.1210/jcem-61-6-1093.
The extrathyroidal metabolism of T4, T3, rT3, and 3',5'-diiodothyronine (3',5'-T2) was studied before and after treatment with 350 mg phenytoin (DPH) daily for 14 days in six hypothyroid patients receiving constant L-T4 replacement. The total and free serum concentrations of the four iodothyronines were reduced by approximately 30% during DPH treatment, whereas the free fractions in serum were unaltered. Concomitantly, serum TSH increased 137% (P less than 0.02). The production rate (PR) of T4 decreased 16% (P less than 0.005), indicating decreased intestinal absorption (bioavailability) of oral L-T4 during DPH treatment. The fractional rate of 5'-deiodination of T4 to T3 increased from 27% to 31% (P less than 0.05), whereas the rate of 5-deiodination of T4 to rT3 decreased from 45% to 25% (P less than 0.05). The urinary excretion of free and conjugated T4 was 2.3% of the T4 PR and was unaffected by DPH. Thus, the amount of T4 metabolized through nondeiodinative pathways apart from urinary excretion increased from 25% to 44% (P less than 0.05). The apparent distribution volume (Vd) of T4 increased (P less than 0.05), whereas the pool size was unchanged. The PR of T3 did not change during DPH treatment, nor did the mean transit time or the cellular clearance. The rT3 PR was reduced by 54% (P less than 0.02) during DPH treatment. Concomitantly, the transit time increased 10-fold (P less than 0.05), whereas Vd and pool size increased 5-fold (P less than 0.01 and P less than 0.05, respectively). The turnover of 3',5'-T2, in contrast to that of the other iodothyronines, did not change significantly during DPH treatment. T3 formation from T4 was measured in liver microsomal fractions from rats treated for 8 days with DPH and was almost identical to that in untreated animals. The data demonstrate that DPH in therapeutic concentrations did not affect serum protein binding of the iodothyronines. DPH reduced the intestinal absorption of T4 and increased the nondeiodinative metabolism of T4. The resulting decrease in total and free serum T4 and T3 was associated with an increase in serum TSH, demonstrating reduced negative feedback on the pituitary. Our data do not support the assumption that DPH induces increased hepatic deiodinating enzyme activity.(ABSTRACT TRUNCATED AT 400 WORDS)
对6例接受持续左旋甲状腺素(L-T4)替代治疗的甲状腺功能减退患者,在每日服用350 mg苯妥英(DPH)共14天治疗前后,研究了T4、T3、反T3(rT3)和3',5'-二碘甲腺原氨酸(3',5'-T2)的甲状腺外代谢情况。在DPH治疗期间,四种碘甲腺原氨酸的血清总浓度和游离浓度降低了约30%,而血清中的游离分数未改变。同时,血清促甲状腺激素(TSH)升高了137%(P<0.02)。T4的生成率(PR)降低了16%(P<0.005),表明在DPH治疗期间口服L-T4的肠道吸收(生物利用度)降低。T4向T3的5'-脱碘分数率从27%增加到31%(P<0.05),而T4向rT3的5-脱碘率从45%降低到25%(P<0.05)。游离和结合T4的尿排泄量为T4 PR的2.3%,且不受DPH影响。因此,除尿排泄外,通过非脱碘途径代谢的T4量从25%增加到44%(P<0.05)。T4的表观分布容积(Vd)增加(P<0.05),而池大小未改变。DPH治疗期间T3的PR未改变,平均转运时间或细胞清除率也未改变。DPH治疗期间rT3 PR降低了54%(P<0.02)。同时,转运时间增加了10倍(P<0.05),而Vd和池大小分别增加了5倍(P<0.01和P<0.05)。与其他碘甲腺原氨酸相反,3',5'-T2的周转率在DPH治疗期间未显著改变。在接受DPH治疗8天的大鼠肝脏微粒体组分中测量了由T4生成T3的情况,其与未治疗动物的情况几乎相同。数据表明,治疗浓度的DPH不影响碘甲腺原氨酸的血清蛋白结合。DPH降低了T4的肠道吸收并增加了T4的非脱碘代谢。血清总T4和游离T4以及T3的降低与血清TSH升高相关,表明对垂体的负反馈减弱。我们的数据不支持DPH诱导肝脱碘酶活性增加的假设。(摘要截短为400字)